TScan Therapeutics Crescita futura
Future criteri di controllo 2/6
TScan Therapeutics is forecast to grow earnings and revenue by 2.3% and 57.2% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be -68.6% in 3 years.
Informazioni chiave
2.3%
Tasso di crescita degli utili
17.8%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 27.1% |
| Tasso di crescita dei ricavi | 57.2% |
| Rendimento futuro del capitale proprio | -68.6% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 27 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
Aug 26Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 10 | -155 | -104 | -132 | 5 |
| 12/31/2025 | 7 | -144 | -102 | -123 | 6 |
| 12/31/2024 | 7 | -130 | -93 | -108 | 6 |
| 6/30/2024 | 12 | -104 | -75 | -71 | N/A |
| 3/31/2024 | 15 | -97 | -70 | -67 | N/A |
| 12/31/2023 | 21 | -89 | -65 | -61 | N/A |
| 9/30/2023 | 17 | -88 | -58 | -54 | N/A |
| 6/30/2023 | 16 | -82 | -82 | -79 | N/A |
| 3/31/2023 | 17 | -73 | -74 | -70 | N/A |
| 12/31/2022 | 14 | -66 | -71 | -67 | N/A |
| 9/30/2022 | 13 | -62 | -70 | -65 | N/A |
| 6/30/2022 | 12 | -61 | -67 | -62 | N/A |
| 3/31/2022 | 11 | -57 | -66 | -59 | N/A |
| 12/31/2021 | 10 | -49 | -59 | -49 | N/A |
| 9/30/2021 | 8 | -42 | -51 | -42 | N/A |
| 6/30/2021 | 6 | -34 | -43 | -34 | N/A |
| 3/31/2021 | 3 | -29 | -14 | -8 | N/A |
| 12/31/2020 | 1 | -26 | -7 | -3 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: TCRX is forecast to remain unprofitable over the next 3 years.
Guadagni vs Mercato: TCRX is forecast to remain unprofitable over the next 3 years.
Guadagni ad alta crescita: TCRX is forecast to remain unprofitable over the next 3 years.
Ricavi vs Mercato: TCRX's revenue (57.2% per year) is forecast to grow faster than the US market (8.9% per year).
Ricavi ad alta crescita: TCRX's revenue (57.2% per year) is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: TCRX is forecast to be unprofitable in 3 years.